ReviewFuture medicinal chemistry2025
Recent advances in quinazolinone derivatives: structure, design and therapeutic potential.
Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Advances in 1,3,4-thiadiazole-based cholinesterase inhibitors: toward novel therapeutics for Alzheimer's disease.Molecular diversity · 2026Review
- New Thieno[3,2-Life (Basel, Switzerland) · 2026Article
- Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies.Chemical biology & drug design · 2026Article
- Synthesis and Biological Evaluation of New Quinazolin-4(3H)-One-Coumarin Hybrids Designed as Anticancer and Antibacterial Agents.International journal of molecular sciences · 2026Article
- Development of coumarin-sulfonate scaffolds for cholinesterase inhibition: experimental and computational studies toward Alzheimer's disease therapy.RSC advances · 2026Article
- QM/MM hybrid simulation of enzyme-Mn synergistic catalysis for quinazolinones: computational determination of activation energy and transition state.Frontiers in chemistry · 2026Article
- Shifting the paradigm of diabetes mellitus therapeutics: synthesis of novel fused pyrrolo-Imidazolidinone derivatives and their kinetic and computational profiling.Journal of computer-aided molecular design · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quinazolinones, a prominent class of heterocyclic compounds, have garnered significant attention due to their diverse biological activities and synthetic versatility. Over the past thirty years, extensive research has been conducted to explore their pharmacological potential, making them an essential scaffold in modern medicinal chemistry.This review provides an analysis of the most common synthesis methods employed for the preparation of quinazolinones, highlighting their efficiency and applicability. Furthermore, it presents an in-depth discussion of their broad-spectrum biological activities, including anticancer, antimicrobial, antifungal, anti-inflammatory, anticonvulsant, anti-Alzheimer's, antiparasitic, antioxidant, antidiabetic, and antiviral properties. By summarizing the latest advancements in quinazolinone research, specifically those made in the past five years, this review aims to serve as a valuable resource for researchers, facilitating easy access to recent studies and promoting further advancements in the field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.